Immunomodulation in Endometrial Cancer

被引：18

作者：

Brooks, Nicole ^{[1
]}

Pouniotis, Dodie S. ^{[1
]}

机构：

[1] RMIT Univ, Sch Med Sci, Bundoora, Vic 3083, Australia

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2009年 / 19卷 / 04期

关键词：

Endometrial cancer; Immunomodulation; Immunotherapy; SEROUS PAPILLARY CARCINOMA; TUMOR-INFILTRATING LYMPHOCYTES; AUTOLOGOUS DENDRITIC CELLS; NATURAL-KILLER RECEPTORS; HUMAN CERVICAL-CARCINOMA; CYTOTOXIC T-LYMPHOCYTES; IN-SITU HYBRIDIZATION; HER-2/NEU OVEREXPRESSION; GENE-EXPRESSION; SERUM-LEVELS;

D O I：

10.1111/IGC.0b013e3181a12f7f

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Endometrial cancer is the most frequent gynecological cancer and the fourth most common cancer in women in the developed world. Over the last decade, immunotherapy has been the focus of intense investigation as a form of cancer treatment whereby the treatment initiates a host immune response ultimately eradicating the tumor. It has been suggested that in endometrial cancer and many other forms of cancer, immunosuppression poses a significant obstacle at inducing antitumor immunity by immunotherapy. This review will look at the different studies that have identified immunomodulation of T cells, cytokines and macrophages, and regulation of apoptotic and angiogenic factors in endometrial cancer patients that may contribute to the inefficiency of immunotherapy.

引用

页码：734 / 740

页数：7

共 96 条

[41]

Liakou Chrysoula I, 2007, Cancer Immun, V7, P10

[42] Immunosuppression in melanoma immunotherapy:: Potential opportunities for intervention [J].

Lizée, G ;

Radvanyi, LG ;

Overwijk, WW ;

Hwu, P .

CLINICAL CANCER RESEARCH, 2006, 12 (07) :2359S-2365S

[43] Apoptosis in cancer [J].

Lowe, SW ;

Lin, AW .

CARCINOGENESIS, 2000, 21 (03) :485-495

[44]

Luczynski W, 2004, ACTA BIOCHIM POL, V51, P1067

[45]

Lurlaro M, 1999, EUR J CLIN INVEST, V29, P793

[46] NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1+ tumors [J].

Maraskovsky, E ;

Sjölander, S ;

Drane, DP ;

Schnurr, M ;

Le, TTT ;

Mateo, L ;

Luft, T ;

Masterman, KA ;

Tai, TY ;

Chen, QY ;

Green, S ;

Sjölander, A ;

Pearse, MJ ;

Lemonnier, FA ;

Chen, WS ;

Cebon, J ;

Suhrbier, A .

CLINICAL CANCER RESEARCH, 2004, 10 (08) :2879-2890

[47] Cutting edge:: Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells [J].

Misra, N ;

Bayry, J ;

Lacroix-Desmazes, S ;

Kazatchkine, MD ;

Kaveri, SV .

JOURNAL OF IMMUNOLOGY, 2004, 172 (08) :4676-4680

[48] B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration [J].

Miyatake, Takashi ;

Tringler, Barbara ;

Liu, Wenhui ;

Liu, Shu-Hui ;

Papkoff, Jackie ;

Enomoto, Takayuki ;

Torkko, Kathleen C. ;

Dehn, Donna L. ;

Swisher, Ashanta ;

Shroyer, Kenneth R. .

GYNECOLOGIC ONCOLOGY, 2007, 106 (01) :119-127

[49] Indoleamine 2,3-dioxygenase and tumor-induced tolerance [J].

Munn, David H. ;

Mellor, Andrew L. .

JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (05) :1147-1154

[50] Tumor cell-induced deactivation of human monocytes [J].

Mytar, B ;

Woloszyn, M ;

Szatanek, R ;

Baj-Krzyworzeka, M ;

Siedlar, M ;

Ruggiero, I ;

Wieckiewicz, J ;

Zembala, M .

JOURNAL OF LEUKOCYTE BIOLOGY, 2003, 74 (06) :1094-1101

← 1 2 3 4 5 6 7 8 9 10 →